Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 12/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3105581 | 0.81 | KDM4E (0.51) | KDM4ECNR2CNR1ALDH1A1HPGD | |
| SCHEMBL2021686 | 0.80 | KDM4E (0.43) | KDM4EALDH1A1HPGDRORCPTGER4 | |
| SCHEMBL3116608 | 0.77 | TTR (0.43) | — | |
| SCHEMBL3104475 | 0.77 | KDM4E (0.45) | KDM4EALDH1A1HPGDRORC | |
| SCHEMBL3106780 | 0.75 | KDM4E (0.52) | KDM4ECNR2CNR1ALDH1A1HPGD | |
| SCHEMBL21162194 | 0.74 | ELOVL6 (0.53) | KDM4EALDH1A1HPGDHTR3EHTR3B | |
| SCHEMBL3113030 | 0.73 | KDM4E (0.52) | KDM4ECNR2CNR1ALDH1A1HPGD | |
| SCHEMBL29643237 | 0.72 | KDM4E (0.76) | KDM4EALDH1A1HPGDRORCNPY5R | |
| SCHEMBL30850787 | 0.72 | KDM4E (1.00) | KDM4ECNR2ALDH1A1HPGDRORC | |
| SCHEMBL2026269 | 0.72 | KDM4E (0.76) | KDM4EALDH1A1HPGDRORCNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056600-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC | 2010-03-04 | — | — | US | claimed |
| EP-2141990-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2010-01-13 | — | — | EP | claimed |
| WO-2008119017-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-10-02 | — | — | WO | claimed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2011068927-A2 | 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20100056600-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC | 2010-03-04 | — | — | US | disclosed |
| US-20100056600-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC | 2010-03-04 | — | — | US | disclosed |
| US-20100056600-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC | 2010-03-04 | — | — | US | disclosed |
| EP-2141990-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119017-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056600-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HSD11B1, HSD3B1, HSD11B2 | KDM4E 4165/4885CNR2 3474/4885CNR1 2396/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | KDM4E 3981/4885CNR2 2776/4885CNR1 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.